Soma Clinical Trials

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)4 trials
• Obesity4 trials
• Type 2 diabetes3 trials
• Chronic kidney disease2 trials
• Primary biliary cholangitis2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Liver cirrhosis1 trial
• Peripheral artery disease1 trial
• Stroke1 trial

Phase

• Phase 39 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Recruiting4 trials
• Completed2 trials

Lead sponsor

• Eli Lilly and Company5 trials
• Boehringer Ingelheim2 trials
• Gilead Sciences1 trial
• Inventiva Pharma1 trial
• Mirum Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Hesham Elgouhari (principal investigator)

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Liver cirrhosis1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source